Evolent Health, Inc (NYSE:EVH) has received an average rating of “Buy” from the seventeen research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $28.56.
Several brokerages have weighed in on EVH. BidaskClub downgraded Evolent Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. ValuEngine downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Robert W. Baird set a $35.00 price target on Evolent Health and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $29.00 price target (down from $33.00) on shares of Evolent Health in a research report on Friday, October 6th.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVH. FMR LLC lifted its stake in Evolent Health by 117.7% in the 2nd quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares in the last quarter. Riverbridge Partners LLC purchased a new position in Evolent Health in the 2nd quarter worth approximately $58,878,000. JPMorgan Chase & Co. raised its position in shares of Evolent Health by 37.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock valued at $136,236,000 after buying an additional 2,026,893 shares during the period. Vanguard Group Inc. raised its position in shares of Evolent Health by 48.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after buying an additional 1,237,941 shares during the period. Finally, Eagle Asset Management Inc. purchased a new stake in shares of Evolent Health during the 2nd quarter valued at approximately $27,577,000. 92.74% of the stock is currently owned by institutional investors and hedge funds.
Evolent Health (EVH) traded down $0.55 during midday trading on Monday, hitting $11.15. The company had a trading volume of 3,966,800 shares, compared to its average volume of 1,214,106. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34. Evolent Health has a 52-week low of $10.35 and a 52-week high of $27.50.
Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The firm had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same period in the prior year, the firm earned ($0.26) EPS. The firm’s revenue was up 79.2% on a year-over-year basis. analysts expect that Evolent Health will post -0.57 earnings per share for the current fiscal year.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.